Navigation Links
FDA gives “black box warning” against three asthma drus

Food and Drug Administration has given a “black box warning” to three asthma drugs//, Foradil, Adavir and Serevent. The FDA panel has advised the manufacturers that the drug should carry clearly the warnings regarding the risks for worsened breathing.

Adavir and Serevent are manufactured by Glaxosmithkline, which contains a compound Salmeterol. Novartis manufacturers the drug Foradil which contains a different long-acting beta-agonist. The U.S. Advisory panel has advised Novartis that they should carry the warnings as mentioned by GlaxosmithKline in their drug Adavir and Serevent.

The resolution of the FDA panel said that consumers and doctors have to know more information about the potential risk of Foradil’s. ``There is information that should come forward'' on potential Foradil risk, said Nancy Sander, an FDA panelist. FDA is reviewing the drugs and advising the pharmaceutical industries to provide more information to the consumers since the withdrawal of Vioxx painkiller of Merck & Co., from the market in September.

Asthma causes inflammation in the airways of the lung leading to lung muscle constriction leading to difficulty in breathing. Though, the FDA panel has approved the stay of Serevent, Adavir and Foradil in the market they insist the drugs should carry additional warnings. Advair and Serevent drugs were both combined with a corticosteroid for better treatment against asthma; the total sales of both these drugs were 2.5 million pounds (4.4 billion dollars).

SMART trial conducted in 1996 by Glaxo on their two drugs Serevent and Adavir was done as advised by FDA. The SMART trial was done with 26,000 recruits and the study was stopped in 2003 after about 50 people died or had severe life-threatening breathing complications after taking Serevent compared with placebo. In the study 20 black people had serious complications or died compared to 5 taking placebo. Though these results should not give misleading conception that blacks should not take the drug. These studies give a clear warning to the consumers about the drug. The pharmaceutical companies should give clear indications about the test results in a clearly understandable way by tabulating and by graphs.

Asthma patients should not stop taking their asthma medications without talking to their doctor. Abruptly stopping asthma medication can result in an asthma attack.

Research of Novartis has found a potential risk for worsened breathing with a higher dose of Foradil than the dosage allowed in the U.S., the FDA said in its review
'"/>




Related medicine news :

1. Microchip gives blind a chance of sight
2. Microchip gives blind a chance of sight
3. Combined scan gives exact cancer diagnosis
4. Tennis gives protection against heart disease lifelong
5. Camera gives hope for detection of breast cancer
6. Pancreas transplant gives hope to type 2 diabetes
7. Trust in Doctor gives better cure
8. Wonder drug Dasatinib gives hopes to leukemia patients
9. 5 Year Old Paralyzed Victim Forgives 50 Year Old Man Who Shot Her
10. ‘Aricept’ drug gives an Alzheimer’s patient reason to smle
11. LA County gives Approval for Reform Plan for King-Drew Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: